Gnana Sunderam, MD
Internal Medicine · East Orange, NJNPI 1164446761
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,730 of the $32,943 with a category attached, or 90.2%. 15 manufacturers reported payments, led by Boehringer Ingelheim at 59.9% of the total. Reporting peaked in 2019 at $12,554 and has fallen 98.6% since, to $170 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $259.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$20K
- GSK$11K
- Dexcom, Inc.$1K
- AstraZeneca$324
- Sanofi-aventis U.S. LLC$163
- Bayer$68
- plus $293 from 9 others
What the payments were for
- Speaking & faculty fees$29,73090%
- Travel & lodging$3651%
- Food & beverage$2,8489%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 28 | $19,730 |
| GSK | 34 | $11,172 |
| Dexcom, Inc. | 30 | $1,193 |
| AstraZeneca | 11 | $324 |
| Sanofi-aventis U.S. LLC | 5 | $163 |
| Bayer | 3 | $68 |
| Embecta Corp. | 1 | $63 |
| Lilly USA, LLC | 4 | $56 |
| AbbVie | 2 | $41 |
| Amgen | 2 | $30 |
| BD | 2 | $29 |
| Nabriva Therapeutics, PLC | 2 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$10,800
- DEXCOM G6 TRANSMITTER$469
- FARXIGA$118
- SOLIQUA 100/33$107
How this compares
$32,943 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $90,372 |
| EnbrelEtanercept | 11 | $87,731 |
| JardianceEmpagliflozin | 153 | $63,205 |
| EliquisApixaban | 143 | $55,286 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $50,494 |
| FarxigaDapagliflozin Propanediol | 69 | $34,824 |
| XareltoRivaroxaban | 80 | $24,644 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 133 | $21,377 |
| TrulicityDulaglutide | 21 | $17,894 |
| TradjentaLinagliptin | 30 | $16,448 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,253 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $10,802 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 324 | $10,331 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $9,057 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $8,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $11,172 | $99,091104 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $19,730 | $90,455206 claims |
| AmgenEnbrel | $30 | $87,73111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $324 | $57,134110 claims |
| Lilly USA, LLCTrulicity | $56 | $17,89421 claims |
| AbbVieCombigan | $41 | $3,98418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in East Orange
- Darshi SunderamEast Orange$530K
- Alexander SalernoEast Orange$91K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.